David Adams

David Adams serves as the Director of Toxicology at REVOLUTION Medicines since October 2023, focusing on patient safety and overseeing nonclinical toxicology programs for small molecule cancer therapeutics. Previously, David held the same title at EQRx from December 2022 to September 2023, where responsibilities included managing toxicology strategies across CROs, directing investigative studies, and ensuring regulatory readiness of submission documents. David's extensive background at GSK spanned over two decades in various roles, including Director and Toxicology Project Specialist, where contributions included the development and execution of toxicology strategies, risk assessments, and regulatory documentation. Earlier professional experiences at Biopool International, the American Red Cross, Wills Eye Hospital, and Pennsylvania Hospital provided foundational expertise in medical technology and laboratory diagnostics. David holds a certification in Medical Technology from Pennsylvania Hospital.